These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20353364)

  • 1. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.
    Khan FA; Minion J; Pai M; Royce S; Burman W; Harries AD; Menzies D
    Clin Infect Dis; 2010 May; 50(9):1288-99. PubMed ID: 20353364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection.
    Ahmad Khan F; Minion J; Al-Motairi A; Benedetti A; Harries AD; Menzies D
    Clin Infect Dis; 2012 Oct; 55(8):1154-63. PubMed ID: 22820541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1998 Oct; 47(RR-20):1-58. PubMed ID: 9809743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy.
    Narendran G; Menon PA; Venkatesan P; Vijay K; Padmapriyadarsini C; Ramesh Kumar S; Bhavani KP; Sekar L; Gomathi SN; Chandrasekhar C; Kumar S; Sridhar R; Swaminathan S
    Clin Infect Dis; 2014 Dec; 59(12):1798-804. PubMed ID: 25156114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
    Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR
    Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
    Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.
    Menzies D; Benedetti A; Paydar A; Martin I; Royce S; Pai M; Vernon A; Lienhardt C; Burman W
    PLoS Med; 2009 Sep; 6(9):e1000146. PubMed ID: 19753109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes of patients with HIV and tuberculosis.
    Nahid P; Gonzalez LC; Rudoy I; de Jong BC; Unger A; Kawamura LM; Osmond DH; Hopewell PC; Daley CL
    Am J Respir Crit Care Med; 2007 Jun; 175(11):1199-206. PubMed ID: 17290042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis and HIV co-infection: a practical therapeutic approach.
    Breen RA; Swaden L; Ballinger J; Lipman MC
    Drugs; 2006; 66(18):2299-308. PubMed ID: 17181373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.
    Singh R; Marshall N; Smith CJ; Reynolds CJ; Breen RA; Bhagani S; Cropley I; Hopkins S; Swaden L; Johnson MA; Lipman MC
    AIDS; 2013 Jan; 27(3):481-4. PubMed ID: 23014518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.
    El-Sadr WM; Perlman DC; Denning E; Matts JP; Cohn DL
    Clin Infect Dis; 2001 Feb; 32(4):623-32. PubMed ID: 11181127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early versus Delayed Antiretroviral Therapy for HIV and Tuberculosis Co-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yan S; Chen L; Wu W; Fu Z; Zhang H; Li Z; Fu C; Mou J; Xue J; Hu Y
    PLoS One; 2015; 10(5):e0127645. PubMed ID: 26000446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy.
    Rawson TM; Brima N; Almajid F; Pozniak AL; Janmohamed A; Mandalia S; Basnayake S; Kellgren L; Copas AJ; Miller RF
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):e84-7. PubMed ID: 25559600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.